Study: Genetic susceptibility to dengue varies with ethnicity | Drug deprives cancer stem cells of vital nutrients | Oxford BioMedica, Bioverativ sign $100M deal to develop gene therapy material
February 16, 2018
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Study: Genetic susceptibility to dengue varies with ethnicity
Researchers from the Institut Pasteur-Paris found that gene variations that influence susceptibility to dengue fever and dengue shock syndrome differ among world populations, according to a study in the journal PLOS Neglected Tropical Diseases. "The particular genetic risk conferred by these genes indicates that Southeast and Northeast Asians are highly susceptible to both phenotypes, while Africans are best protected against DSS and Europeans best protected against DF, but the most susceptible to DSS," the study team wrote.
GenomeWeb Daily News (free registration) (2/15) 
LinkedIn Twitter Facebook Google+ Email
Science & Health
Drug deprives cancer stem cells of vital nutrients
Diphenyleneiodonium selectively inhibited cancer stem cells' ability to produce essential vitamins, starving the cells and rendering them dormant and thus more vulnerable to conventional treatment, researchers reported in Aging. The drug did not produce toxic side effects, the researchers said.
Specialty Pharmacy Times (2/14) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
Oxford BioMedica, Bioverativ sign $100M deal to develop gene therapy material
Bioverativ awarded a $100 million contract to the UK's Oxford BioMedica to develop lentiviral vectors for use in Bioverativ's hemophilia gene therapies. Oxford BioMedica will receive an upfront payment of $5 million and will be eligible for several milestone payments, with a potential value exceeding $100 million, as well as royalties on sales of Bioverativ's hemophilia therapies that are under development.
Genetic Engineering & Biotechnology News (2/15),  Reuters (2/15) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
Firm receives 5-year contract with VA for device to collect blood
The Department of Veterans Affairs has awarded a five-year contract to Magnolia Medical Technologies to supply the Steripath Initial Specimen Diversion Device for blood culture collection.
360Dx (tiered subscription model) (2/13) 
LinkedIn Twitter Facebook Google+ Email
Agios' AML therapy accepted under priority review by FDA
Agios Pharmaceuticals' new-drug application for ivosidenib, which is being developed as a treatment for patients with isocitrate dehydrogenase 1 mutation-positive relapsed/refractory acute myeloid leukemia, was accepted for priority review by the FDA. The PDUFA date for the drug is Aug. 21.
Seeking Alpha (free registration) (2/15) 
LinkedIn Twitter Facebook Google+ Email
Association News
Hot topics in the AABB HUB
Topics creating a buzz this week in the AABB HUB include intraoperative blood recovery, the appropriate dose of Rh immune globulin, ISBT labels for pooled apheresis plasma and blood collection bags. To sign up for email alerts for new posts or responses, click the envelope icon on the left tab of the group. Select one of the threads below to follow the discussion or submit a comment.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Clinical Nurse Supervisor, Therapeutic Apheresis Service
Because I cannot do everything, I will not refuse to do the something that I can do.
Edward Everett Hale,
writer and clergyman
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information